Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of “Moderate Buy” from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $55.5556.

A number of research analysts recently issued reports on the company. HC Wainwright raised their price target on Terns Pharmaceuticals from $20.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. JMP Securities set a $35.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th. Oppenheimer increased their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Finally, UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th.

Terns Pharmaceuticals Price Performance

Shares of TERN opened at $34.33 on Friday. Terns Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $48.26. The stock has a market cap of $3.09 billion, a PE ratio of -33.33 and a beta of -0.28. The firm has a fifty day moving average price of $36.04 and a 200 day moving average price of $18.01.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. As a group, equities analysts expect that Terns Pharmaceuticals will post -1.19 EPS for the current fiscal year.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the sale, the chief executive officer directly owned 138,976 shares of the company’s stock, valued at $5,294,985.60. This represents a 33.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares in the company, valued at $1,942,578.05. This trade represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 165,763 shares of company stock worth $5,752,450 in the last quarter. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several institutional investors have recently bought and sold shares of TERN. Candriam S.C.A. lifted its stake in shares of Terns Pharmaceuticals by 9.9% in the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock worth $8,834,000 after acquiring an additional 214,266 shares during the period. DLD Asset Management LP purchased a new position in Terns Pharmaceuticals during the second quarter worth about $138,000. Franklin Resources Inc. purchased a new position in Terns Pharmaceuticals during the second quarter worth about $4,765,000. FNY Investment Advisers LLC acquired a new stake in Terns Pharmaceuticals in the fourth quarter valued at about $80,000. Finally, Tema Etfs LLC purchased a new stake in Terns Pharmaceuticals in the 4th quarter valued at approximately $414,000. 98.26% of the stock is owned by institutional investors and hedge funds.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.